Four Very Reliable Methods For ZD1839
2 (20.1) kg in the adjunctive edivoxetine group and was 83.5 (21.7) kg in the adjunctive placebo group. Mean change (SE) from baseline at the last visit was ?0.8 kg and 0.22 kg, respectively, in the adjunctive edivoxetine and adjunctive placebo group; the mean difference from ZD1839 adjunctive placebo was ?1.0 kg (pNK cell Discussion Edivoxetine is one of three selective NRIs that have been investigated as adjunctive treatment to SSRI antidepressants in MDD patients. The other two are reboxetine and atomoxetine, and neither have an indication for adjunctive therapy in MDD. Reboxetine was studied as adjunctive treatment to SSRI antidepressants in a small (n=61) 6-week open-label trial [13]. The SSRIs included in that study were fluoxetine, paroxetine, sertraline, citalopram, and fluvoxamine. The safety outcomes of the adjunctive reboxetine study only included reporting the most common TEAEs (increased sweating, GSI-IX purchase dry mouth, tremor, nervousness, insomnia, and urinary hesitancy), and there were no SAEs. Neither vital sign changes nor clinical laboratory changes were reported, which limits tolerability and safety comparisons to adjunctive edivoxetine. Atomoxetine was studied as adjunctive treatment in patients with MDD who were partial responders to sertraline [14]. The most common TEAEs reported with adjunctive atomoxetine were dry mouth, insomnia, and constipation. There were no serious safety concerns or clinically meaningful changes in laboratory outcomes reported. Adjunctive treatment to SSRI antidepressants with edivoxetine was generally well-tolerated as evidenced by high study completion rates (85.2%) and low rates of discontinuation due to adverse events (5.0%). The rates of discontinuation due to adverse events in this analysis were within the range reported in two acute placebo-controlled trials of edivoxetine monotherapy in patients with MDD: 1.5�C9.2% [15,16]. In addition, TEAEs associated with adjunctive edivoxetine, with the exception for tachycardia in this study, were comparable with those reported in the two placebo-controlled trials of edivoxetine monotherapy: constipation, dizziness, dry mouth, erectile dysfunction, headache, increased heart rate, hyperhidrosis, insomnia, and nausea.
